AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

United States Revenue

United States Revenue % Chg.

United States Revenue Common Size

International Revenue

International Revenue % Chg.

International Revenue Common Size

Total Revenue by Geography

Total Revenue by Geography Common Size

Total Revenue by Geography % Chg.

Revenue by Geography

Immunology Revenue

Immunology Revenue % Chg.

Immunology Revenue Common Size

Neuroscience Revenue

Neuroscience Revenue % Chg.

Neuroscience Revenue Common Size

Oncology Revenue

Oncology Revenue % Chg.

Oncology Revenue Common Size

Aesthetics Revenue

Aesthetics Revenue % Chg.

Aesthetics Revenue Common Size

Eye Care Revenue

Eye Care Revenue % Chg.

Eye Care Revenue Common Size

Women's Health Revenue

Women's Health Revenue % Chg.

Women's Health Revenue Common Size

Other Key Products Revenue

Other Key Products Revenue % Chg.

Other Key Products Revenue Common Size

All Other Revenue

All Other Revenue % Chg.

All Other Revenue Common Size

Other Revenue

Other Revenue % Chg.

Other Revenue Common Size

Total Revenue

Total Revenue Common Size

Total Revenue % Chg.

Revenue by Geography	LTM	Dec '24	Dec '23
United States Revenue	45,543	43,029	41,883
International Revenue	14,101	13,305	12,435
Total Revenue by Geography	59,644	56,334	54,318

Revenue	LTM	Dec '24	Dec '23
Immunology Revenue	29,074	26,682	26,136
Neuroscience Revenue	10,315	8,999	7,717
Oncology Revenue	6,682	6,555	5,915
Aesthetics Revenue	4,872	5,176	5,294
Eye Care Revenue	2,175	2,242	2,415
Women's Health Revenue	—	—	—
Other Key Products Revenue	3,764	3,648	3,806
All Other Revenue	2,762	3,032	3,035
Other Revenue	—	—	—
Total Revenue	59,644	56,334	54,318